ATE473229T1 - Tricyclische verbindungen und deren verwendung als mglur1-antagonisten - Google Patents

Tricyclische verbindungen und deren verwendung als mglur1-antagonisten

Info

Publication number
ATE473229T1
ATE473229T1 AT05761566T AT05761566T ATE473229T1 AT E473229 T1 ATE473229 T1 AT E473229T1 AT 05761566 T AT05761566 T AT 05761566T AT 05761566 T AT05761566 T AT 05761566T AT E473229 T1 ATE473229 T1 AT E473229T1
Authority
AT
Austria
Prior art keywords
tricyclic compounds
mglur1 antagonists
mglur1
antagonists
tricyclic
Prior art date
Application number
AT05761566T
Other languages
English (en)
Inventor
Julius Matasi
Deen Tulshian
Duane Burnett
Wen-Lian Wu
Peter Korakas
Lisa Silverman
Thavalakulamgara Sasikumar
Li Qiang
Martin Domalski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE473229T1 publication Critical patent/ATE473229T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00—Other synthetic dyes of known constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05761566T 2004-06-15 2005-06-14 Tricyclische verbindungen und deren verwendung als mglur1-antagonisten ATE473229T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992004P 2004-06-15 2004-06-15
PCT/US2005/020972 WO2006002051A1 (en) 2004-06-15 2005-06-14 Tricyclic compounds and their use as mglur1 antagonists

Publications (1)

Publication Number Publication Date
ATE473229T1 true ATE473229T1 (de) 2010-07-15

Family

ID=35044971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05761566T ATE473229T1 (de) 2004-06-15 2005-06-14 Tricyclische verbindungen und deren verwendung als mglur1-antagonisten

Country Status (13)

Country Link
US (2) US7485648B2 (de)
EP (1) EP1765829B1 (de)
JP (1) JP2008502693A (de)
CN (1) CN101001862A (de)
AR (1) AR049300A1 (de)
AT (1) ATE473229T1 (de)
CA (1) CA2571012A1 (de)
DE (1) DE602005022191D1 (de)
ES (1) ES2348453T3 (de)
MX (1) MXPA06014913A (de)
PE (1) PE20060526A1 (de)
TW (1) TWI292400B (de)
WO (1) WO2006002051A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2006081072A1 (en) * 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
ATE516292T1 (de) * 2005-08-19 2011-07-15 Schering Corp Kondensierte tricyclische mglur1-antagonisten als therapeutische mittel
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
EP1829879A1 (de) * 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Amino Pyrimidine Verbindungen zur Behandlung von entzündlichen Erkrankungen
CA2672327A1 (en) * 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
AU2009257602B2 (en) 2008-06-10 2015-10-08 Abbvie Inc. Novel tricyclic compounds
CA2726114A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP4782062A2 (de) 2009-12-01 2026-07-29 AbbVie Inc. Neuartige tricyclische verbindungen
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (de) 2010-02-02 2014-10-15 Novartis AG Cyclohexylamidderivate als crf-rezeptorantagonisten
EP2603079B1 (de) * 2010-08-12 2018-09-19 Merck Sharp & Dohme Corp. Positive allosterische modulatoren von mglur2
HK1210732A1 (en) * 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
CN103265478B (zh) * 2013-05-20 2015-09-30 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
WO2014187291A1 (zh) * 2013-05-20 2014-11-27 中国人民解放军军事医学科学院微生物流行病研究所 巯基烟酸类化合物及其制备方法与用途
CN104161757B (zh) * 2013-05-20 2016-06-22 中国人民解放军军事医学科学院微生物流行病研究所 巯基烟酸类化合物的用途
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
KR102474326B1 (ko) 2016-06-22 2022-12-05 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제
EP3558309B1 (de) 2016-11-07 2023-07-26 Vanderbilt University Positive allosterische modulatoren des muskarinischen acetylcholinrezeptors m4
EP3534901B1 (de) 2016-11-07 2022-06-22 Vanderbilt University Positive allosterische modulatoren des muskarinischen acetylcholinrezeptors m4
JP7097623B2 (ja) 2016-11-07 2022-07-08 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
WO2019113174A1 (en) 2017-12-05 2019-06-13 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CN111757882B (zh) * 2018-01-05 2023-08-22 Ac免疫有限公司 用于治疗、减轻或预防与Tau聚集体相关的病症的化合物
WO2022263557A1 (en) * 2021-06-15 2022-12-22 Glaxosmithkline Intellectual Property Development Limited Pharmaceutical compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
SV2002000205A (es) * 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002062803A1 (en) * 2001-02-08 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Thienopyrimidine derivative
CA2555132A1 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof

Also Published As

Publication number Publication date
MXPA06014913A (es) 2007-03-21
EP1765829A1 (de) 2007-03-28
US20060009477A1 (en) 2006-01-12
JP2008502693A (ja) 2008-01-31
TW200609231A (en) 2006-03-16
DE602005022191D1 (de) 2010-08-19
PE20060526A1 (es) 2006-07-13
CN101001862A (zh) 2007-07-18
US20090082336A1 (en) 2009-03-26
AR049300A1 (es) 2006-07-12
US7485648B2 (en) 2009-02-03
CA2571012A1 (en) 2006-01-05
ES2348453T3 (es) 2010-12-07
TWI292400B (en) 2008-01-11
EP1765829B1 (de) 2010-07-07
WO2006002051A1 (en) 2006-01-05
HK1097269A1 (en) 2007-06-22

Similar Documents

Publication Publication Date Title
DE602005022191D1 (de) Tricyclische verbindungen und deren verwendung als mglur1-antagonisten
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
DE602005010961D1 (de) Phenylcarbazole basierte Verbindungen und deren Verwendung als organische Elektroluminiszierende Vorrichtung
DE602005022116D1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
ATE440095T1 (de) Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist
ATE437870T1 (de) Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
ATE473214T1 (de) 2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
DE602005025110D1 (de) Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
ATE520681T1 (de) N-thioanthranilamidverbindungen und ihre verwendung als pestizide
ATE378338T1 (de) Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
ATE518872T1 (de) Trizyklische verbindungen und deren verwendung als glucocorticoidrezeptormodulatoren
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
DE602007008572D1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
DE602005022169D1 (de) Polymerisierbare verbindungen und verwendung davon
DK2783682T3 (da) Farmaceutisk sammensætning omfattende pimobendan
ATE417045T1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE487707T1 (de) (6-flu0r-benz0äl, 3üdioxolyl)-morpholin-4-yl- methanone und deren verwendung als cbl-liganden
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
ATE468326T1 (de) Verbindungen zur verstärkung der glutamatrezeptorwirkung und deren verwendung in der medizin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties